**Abstract**

**Objective:** To describe the clinical and therapeutic features of 120 panic disorder (PD) patients treated for 3 years with clonazepam, paroxetine, or clonazepam + paroxetine and their follow-up for 6 years after the treatment.

**Method**: A prospective open study with 120 PD patients randomized to 2 mg/day clonazepam or 40 mg/day paroxetine. Poor responders were switched after 8 weeks to combined treatment with ∼2 mg/day clonazepam + ∼40 mg/day paroxetine. Tapered withdrawal of the treatment was performed after 3 years. Efficacy, safety, and cumulative relapse and remission were studied over the following 6 years.

**Results:** 94 patients completed 3 years treatment. All were free of panic attacks since at least one year before undergoing tapered drug withdrawal. In annually studied patients the relapse rates were similar after the 3 treatments with a marginal advantage of clonazepam over the combination and paroxetine at the first year after drug withdrawal. Cumulative relapses rate were 41%, 77%, and 94% at years 1, 4, and 6. 90% of the annually followed patients were during the 6 years of follow up in average in remission (partial: 54%, full: 36%); 73% were PA-free, 91% had a GCI-S score of 1, and 39% HAMA scores of 5--10; 33% needed drug treatment in each follow-up year. Both treatments displayed similarly high efficacy, but clonazepam was better tolerated. Results in patients studied at the end of follow-up only were similar, but somewhat less favorable: 88% were in remission, 72% were PA-free, 62% had a CGI-S score of 1 and 30% a HAMA of 5--10, with 39% needing PD treatment.

**Conclusion**: PD is a chronic disorder, with many patients relapsing despite being asymptomatic at least one year after 3 years treatment. Paroxetine and clonazepam were associated with similar long-term prognoses but clonazepam was better tolerated.
